Company intelligence / Profile preview
Zelos Therapeutics
- Ownership
- Private
- Employees
- ~4
- Development stage
- Other
Overview
ZT‑031 (Ostabolin-C), a proprietary cyclic parathyroid hormone analog, demonstrated strong bone formation activity with rapid onset and clinically significant increases in bone mineral density at low toxicity doses. The subcutaneous formulation completed a successful 12-month Phase 2 trial in postmenopausal women with low bone mass. Intranasal and inhaled versions were also developed through partnerships.[6] The company planned to enter Phase 3 trials before restructuring as Azelon Pharmaceuticals.[7] As Azelon, the nasal spray ZT‑034 entered early clinical studies.
- Therapeutic areas
- OtherEndocrinologyNephrology
- Modalities
- Peptides (parathyroid hormone analogs)Small proteins[6][8][10]
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Zelos Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zelos Therapeutics.